1. Product
Overview
1.1. Market
Definition
1.2. Scope
of the Market
1.2.1. Markets
Covered
1.2.2. Years
Considered for Study
1.2.3. Key
Market Segmentations
2. Research
Methodology
2.1. Objective
of the Study
2.2. Baseline
Methodology
2.3. Key
Industry Partners
2.4. Major
Association and Secondary Sources
2.5. Forecasting
Methodology
2.6. Data
Triangulation & Validation
2.7. Assumptions
and Limitations
3. Executive
Summary
3.1. Overview
of the Market
3.2. Overview
of Key Market Segmentations
3.3. Overview
of Key Market Players
3.4. Overview
of Key Regions/Countries
3.5. Overview
of Market Drivers, Challenges, Trends
4. Voice
of Customer
5. France
Peripheral Blood Mononuclear Cells (PBMCs) Market Outlook
5.1. Market
Size & Forecast
5.1.1. By
Value
5.2. Market
Share & Forecast
5.2.1. By Product
(Cryopreserved or Frozen PBMC, Cultured or Fresh PBMC, Peripheral Blood
Mononuclear Cell Isolation & Viability Kits)
5.2.2. By
Application (Immunology, Infectious Disease, Hematology, Others)
5.2.3. By
Technique (Density Gradient Centrifugation Process, Leukapheresis)
5.2.4. By
Source (Human, Animals)
5.2.5. By
Region
5.2.6. By
Company (2023)
5.3. Market
Map
5.3.1. By Product
5.3.2. By
Application
5.3.3. By
Technique
5.3.4. By Source
5.3.5. By Region
6. Northern
France Peripheral Blood Mononuclear Cells (PBMCs) Market Outlook
6.1. Market
Size & Forecast
6.1.1. By
Value
6.2. Market
Share & Forecast
6.2.1. By
Product (Cryopreserved or Frozen PBMC, Cultured or Fresh PBMC, Peripheral Blood
Mononuclear Cell Isolation & Viability Kits)
6.2.2. By
Application (Immunology, Infectious Disease, Hematology, Others)
6.2.3. By
Technique (Density Gradient Centrifugation Process, Leukapheresis)
6.2.4. By
Source (Human, Animals)
7. Southern
France Peripheral Blood Mononuclear Cells (PBMCs) Market Outlook
7.1. Market
Size & Forecast
7.1.1. By
Value
7.2. Market
Share & Forecast
7.2.1. By
Product (Cryopreserved or Frozen PBMC, Cultured or Fresh PBMC, Peripheral Blood
Mononuclear Cell Isolation & Viability Kits)
7.2.2. By
Application (Immunology, Infectious Disease, Hematology, Others)
7.2.3. By
Technique (Density Gradient Centrifugation Process, Leukapheresis)
7.2.4. By
Source (Human, Animals)
8. Western
France Peripheral Blood Mononuclear Cells (PBMCs) Market Outlook
8.1. Market
Size & Forecast
8.1.1. By
Value
8.2. Market
Share & Forecast
8.2.1. By
Product (Cryopreserved or Frozen PBMC, Cultured or Fresh PBMC, Peripheral Blood
Mononuclear Cell Isolation & Viability Kits)
8.2.2. By
Application (Immunology, Infectious Disease, Hematology, Others)
8.2.3. By
Technique (Density Gradient Centrifugation Process, Leukapheresis)
8.2.4. By
Source (Human, Animals)
9. Central
France Peripheral Blood Mononuclear Cells (PBMCs) Market Outlook
9.1. Market
Size & Forecast
9.1.1. By
Value
9.2. Market
Share & Forecast
9.2.1. By
Product (Cryopreserved or Frozen PBMC, Cultured or Fresh PBMC, Peripheral Blood
Mononuclear Cell Isolation & Viability Kits)
9.2.2. By
Application (Immunology, Infectious Disease, Hematology, Others)
9.2.3. By
Technique (Density Gradient Centrifugation Process, Leukapheresis)
9.2.4. By
Source (Human, Animals)
10. Eastern
France Peripheral Blood Mononuclear Cells (PBMCs) Market Outlook
10.1. Market
Size & Forecast
10.1.1. By
Value
10.2. Market
Share & Forecast
10.2.1. By
Product (Cryopreserved or Frozen PBMC, Cultured or Fresh PBMC, Peripheral Blood
Mononuclear Cell Isolation & Viability Kits)
10.2.2. By
Application (Immunology, Infectious Disease, Hematology, Others)
10.2.3. By
Technique (Density Gradient Centrifugation Process, Leukapheresis)
10.2.4. By
Source (Human, Animals)
11. Southwestern
France Peripheral Blood Mononuclear Cells (PBMCs) Market Outlook
11.1. Market
Size & Forecast
11.1.1. By
Value
11.2. Market
Share & Forecast
11.2.1. By
Product (Cryopreserved or Frozen PBMC, Cultured or Fresh PBMC, Peripheral Blood
Mononuclear Cell Isolation & Viability Kits)
11.2.2. By
Application (Immunology, Infectious Disease, Hematology, Others)
11.2.3. By
Technique (Density Gradient Centrifugation Process, Leukapheresis)
11.2.4. By
Source (Human, Animals)
12. Market
Dynamics
12.1. Drivers
12.2. Challenges
13. Market
Trends & Developments
13.1. Recent
Developments
13.2. Mergers
& Acquisitions
13.3. Product
Launches
14. Policy
& Regulatory Landscape
15. Porter’s
Five Forces Analysis
15.1. Competition
in the Industry
15.2. Potential
of New Entrants
15.3. Power
of Suppliers
15.4. Power
of Customers
15.5. Threat
of Substitute Products
16. France
Economic Profile
17. Competitive
Landscape
17.1. Charles River Laboratories
17.1.1. Business
Overview
17.1.2. Product
Offerings
17.1.3. Recent
Developments
17.1.4. Financials
(As Reported)
17.1.5. Key
Personnel
17.1.6. SWOT
Analysis
17.2. Lonza
Group AG
17.3. Bio-Rad Laboratories Inc
17.4. ABCAM
17.5. BioLegend Europe BV
17.6. ZEN-Bio Inc
17.7. Creative Bioarray
(EUROMEDEX, Interchim)
17.8. Miltenyi Biotec SAS
17.9. STEMCELL Technologies
18. Strategic
Recommendations
19. About Us & Disclaimer